MX2016014740A - Un metodo para el tratamiento de trastornos del movimiento con befiradol. - Google Patents
Un metodo para el tratamiento de trastornos del movimiento con befiradol.Info
- Publication number
- MX2016014740A MX2016014740A MX2016014740A MX2016014740A MX2016014740A MX 2016014740 A MX2016014740 A MX 2016014740A MX 2016014740 A MX2016014740 A MX 2016014740A MX 2016014740 A MX2016014740 A MX 2016014740A MX 2016014740 A MX2016014740 A MX 2016014740A
- Authority
- MX
- Mexico
- Prior art keywords
- befiradol
- movement disorders
- administration
- treating movement
- patient
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- PKZXLMVXBZICTF-UHFFFAOYSA-N befiradol Chemical compound N1=CC(C)=CC=C1CNCC1(F)CCN(C(=O)C=2C=C(Cl)C(F)=CC=2)CC1 PKZXLMVXBZICTF-UHFFFAOYSA-N 0.000 title abstract 3
- 229950007200 befiradol Drugs 0.000 title abstract 3
- 208000016285 Movement disease Diseases 0.000 title abstract 2
- 206010028813 Nausea Diseases 0.000 abstract 1
- 208000002173 dizziness Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a un método para el tratamiento de trastornos del movimiento comprendiendo la administración, a un paciente en la necesidad de ello, de una cantidad eficaz de befiradol, donde en el paso de la administración se le proporciona a un paciente una concentración máxima de befiradol en plasma por debajo de los 15 ng/ml, misma que se obtiene después de más de 4 horas posteriores a la administración, dicho método minimizando los efectos secundarios del mareo y la náusea. También se describen composiciones farmacéuticas de liberación sostenida que pueden ser utilizadas de acuerdo con este método.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462022462P | 2014-07-09 | 2014-07-09 | |
| PCT/EP2015/065763 WO2016005527A1 (en) | 2014-07-09 | 2015-07-09 | A method for treating movement disorders with befiradol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016014740A true MX2016014740A (es) | 2017-03-06 |
| MX374938B MX374938B (es) | 2025-03-06 |
Family
ID=53682662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016014740A MX374938B (es) | 2014-07-09 | 2015-07-09 | Un método para el tratamiento de trastornos del movimiento con befiradol. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10548885B2 (es) |
| EP (1) | EP3131549B1 (es) |
| JP (2) | JP6636458B2 (es) |
| KR (1) | KR102533428B1 (es) |
| CN (1) | CN106456622B (es) |
| AU (1) | AU2015286675B2 (es) |
| CA (1) | CA2946829C (es) |
| DK (1) | DK3131549T3 (es) |
| ES (1) | ES2668379T3 (es) |
| HU (1) | HUE037945T2 (es) |
| MX (1) | MX374938B (es) |
| PL (1) | PL3131549T3 (es) |
| PT (1) | PT3131549T (es) |
| RU (1) | RU2702101C2 (es) |
| WO (1) | WO2016005527A1 (es) |
| ZA (1) | ZA201607419B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2668379T3 (es) * | 2014-07-09 | 2018-05-17 | Pierre Fabre Médicament | Método para el tratamiento de trastornos del movimiento con befiradol |
| WO2018057576A1 (en) | 2016-09-22 | 2018-03-29 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds |
| WO2019016357A1 (en) | 2017-07-20 | 2019-01-24 | Neurolixis | USE OF SELECTIVE 5-HT1A SEROTONIN RECEPTOR AGONISTS TO TREAT THE ADVERSE EFFECTS OF VMAT INHIBITORS |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
| FR2755967B1 (fr) | 1996-11-21 | 1999-01-29 | Pf Medicament | Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments |
| US6060345A (en) * | 1997-04-21 | 2000-05-09 | Advanced Micro Devices, Inc. | Method of making NMOS and PMOS devices with reduced masking steps |
| FR2820743B1 (fr) | 2001-02-09 | 2005-02-25 | Pf Medicament | Procede et intermediaires de synthese pour la preparation de derives de pyridin-2-yl-methylamine |
| US7964219B2 (en) | 2004-08-12 | 2011-06-21 | Qps, Llc | Pharmaceutical compositions for controlled release delivery of biologically active compounds |
| US7040843B1 (en) | 2005-03-17 | 2006-05-09 | Great Lakes Custom Tool Mfg., Inc. | Flooring hollow back relief cutting tool and method |
| GB2462022B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof |
| WO2011008546A2 (en) | 2009-06-29 | 2011-01-20 | Capricorn Pharma, Inc. | Solid and semi-solid dosage forms and systems and methods for forming and packaging thereof |
| KR20120118031A (ko) | 2010-02-12 | 2012-10-25 | 닛산 가가쿠 고교 가부시키 가이샤 | 서방성 제제 |
| BR112012024019B1 (pt) * | 2010-03-24 | 2021-10-19 | Jazz Phamaceuticals, Inc | Forma de dosagem de liberação controlada para administração oral |
| WO2012030314A1 (en) | 2010-09-01 | 2012-03-08 | Mithridion, Inc. | Compositions comprising 5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine, and methods of administering same |
| CN105193809B (zh) * | 2010-10-15 | 2019-07-16 | 康特拉医药公司 | 用于治疗运动障碍的血清素受体激动剂组合物 |
| WO2013004249A1 (en) | 2011-07-05 | 2013-01-10 | Concit Pharma Aps | The use of serotonin receptor agonists for treatment of movement disorders |
| MY169068A (en) | 2012-04-18 | 2019-02-12 | Contera Pharma Aps | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
| ES2668379T3 (es) * | 2014-07-09 | 2018-05-17 | Pierre Fabre Médicament | Método para el tratamiento de trastornos del movimiento con befiradol |
| WO2025035048A1 (en) | 2023-08-09 | 2025-02-13 | Via Separations, Inc. | Filtration apparatus comprising polymer modified graphene oxide membranes |
-
2015
- 2015-07-09 ES ES15739213.5T patent/ES2668379T3/es active Active
- 2015-07-09 RU RU2016143875A patent/RU2702101C2/ru active
- 2015-07-09 PT PT157392135T patent/PT3131549T/pt unknown
- 2015-07-09 US US15/310,415 patent/US10548885B2/en active Active
- 2015-07-09 CA CA2946829A patent/CA2946829C/en active Active
- 2015-07-09 DK DK15739213.5T patent/DK3131549T3/en active
- 2015-07-09 EP EP15739213.5A patent/EP3131549B1/en active Active
- 2015-07-09 JP JP2016567577A patent/JP6636458B2/ja active Active
- 2015-07-09 KR KR1020167031277A patent/KR102533428B1/ko active Active
- 2015-07-09 CN CN201580025182.0A patent/CN106456622B/zh active Active
- 2015-07-09 MX MX2016014740A patent/MX374938B/es active IP Right Grant
- 2015-07-09 AU AU2015286675A patent/AU2015286675B2/en active Active
- 2015-07-09 PL PL15739213T patent/PL3131549T3/pl unknown
- 2015-07-09 HU HUE15739213A patent/HUE037945T2/hu unknown
- 2015-07-09 WO PCT/EP2015/065763 patent/WO2016005527A1/en active Application Filing
-
2016
- 2016-10-27 ZA ZA2016/07419A patent/ZA201607419B/en unknown
-
2018
- 2018-04-12 JP JP2018076772A patent/JP6824924B2/ja active Active
-
2019
- 2019-12-17 US US16/717,019 patent/US11090298B2/en active Active
-
2021
- 2021-06-25 US US17/359,182 patent/US20210338646A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016005527A1 (en) | 2016-01-14 |
| RU2016143875A3 (es) | 2019-02-01 |
| KR20170029407A (ko) | 2017-03-15 |
| CA2946829A1 (en) | 2016-01-14 |
| US11090298B2 (en) | 2021-08-17 |
| RU2016143875A (ru) | 2018-08-10 |
| MX374938B (es) | 2025-03-06 |
| CN106456622A (zh) | 2017-02-22 |
| JP2017524651A (ja) | 2017-08-31 |
| EP3131549A1 (en) | 2017-02-22 |
| ZA201607419B (en) | 2023-12-20 |
| ES2668379T3 (es) | 2018-05-17 |
| RU2702101C2 (ru) | 2019-10-04 |
| PL3131549T3 (pl) | 2018-09-28 |
| US20200138800A1 (en) | 2020-05-07 |
| JP2018138568A (ja) | 2018-09-06 |
| PT3131549T (pt) | 2018-07-04 |
| KR102533428B1 (ko) | 2023-05-16 |
| BR112016026648A2 (pt) | 2017-08-15 |
| US10548885B2 (en) | 2020-02-04 |
| DK3131549T3 (en) | 2018-05-28 |
| EP3131549B1 (en) | 2018-03-28 |
| JP6636458B2 (ja) | 2020-01-29 |
| JP6824924B2 (ja) | 2021-02-03 |
| US20170239231A1 (en) | 2017-08-24 |
| AU2015286675A1 (en) | 2016-11-24 |
| CA2946829C (en) | 2018-05-22 |
| HUE037945T2 (hu) | 2018-09-28 |
| BR112016026648A8 (pt) | 2021-07-20 |
| AU2015286675B2 (en) | 2017-08-24 |
| US20210338646A1 (en) | 2021-11-04 |
| CN106456622B (zh) | 2020-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22023220A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| CO2017012268A2 (es) | Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b | |
| NI201800039A (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue | |
| NI201800040A (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| DOP2017000049A (es) | Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae | |
| CO2018009559A2 (es) | Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue | |
| CL2017001822A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| UY36339A (es) | Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| MX2016014740A (es) | Un metodo para el tratamiento de trastornos del movimiento con befiradol. | |
| MX2016011025A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| EA201401332A1 (ru) | Инъекционная композиция на основе витаминов группы b и лидокаина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |